Despite artificial intelligence’s growing role in drug research, a fully AI-generated molecule has yet to advance from discovery all the way through clinical development. A novel molecule may eventually meet that goal, but some industry observers say it’s too early to focus on winning a race that has many twists and turns yet to come.
At HLTH 2023, I had dozens of conversations with providers, digital health investors, startup CEOs and other players in the healthcare industry. When I got home, I compiled seven refreshingly honest takes I heard from them while at the conference.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
At HLTH, Bessemer investors Sofia Guerra and Steve Kraus detailed four predictions about where they think the digital health world is headed in 2024. One of these was that "services-as-software" will emerge as a new category of healthcare AI. Another was that some healthcare technology vendors will have to rethink their distribution models and rely on indirect monetization strategies.
The report maps out the health tech sector's current position in the innovation hype cycle, which business models are most resilient, and how the industry can move out of the trough of disillusionment. It also offered predictions for health tech trends in 2024.
Investment trends will be a big theme at the HLTH event at the Las Vegas Convention Center October 8-11. In the runup to the conference, investors from Bessemer Venture Partners, Cleveland Clinic Innovations, Third Culture Capital and Intuitive Ventures offered their takes on 2023 investments.
A new study from Bessemer Venture Partners analyzed more than 100 venture-backed healthcare companies to determine the best strategies to scale to $100 million in annual recurring revenue. The report laid out a few main lessons health tech companies should know, such as the importance of nurturing relationships with early customers and making sure efficiency metrics are paid close attention.
This year has been marked by a rise in health tech layoffs, reduced health tech investment and the continued rise of retail health. What does this mean for healthcare investment in 2023?
Check out new developments from Carrum Health, Springboard Enterprises, Bessemer Venture Partners, and more.
Digital health startup raised a $90 million funding round led by Bessemer Venture Partners. The company builds software tools to help patients with joint and back pain.
Bessemer Venture Partners and Columbia Capital led the round, and Blue Heron Capital and California Health Care Foundation also participated.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The Deep Health Seed Program will invest $100,000 to $2 million in the companies it targets, according to a report by TechCrunch.
"The funding allows us to deepen the clinical capabilities of the software without slowing our geographic expansion," said Collective Medical CEO Chris Klomp.
Bessemer Venture Partners and Columbia Capital co-led the investment round. Both had participated in Verato's Series A in 2015.
Last Friday on our weekly MedHeads broadcast, we had a discussion about investment trends in digital health, current obstacles and what current startups should be conscious of going in.
This week for MedHeads we'll be joined for this discussion by Dr. Dan Peterson, founder of Teqqa, which is focused on improving the treatment of infectious diseases and addressing the growing problem of antibiotic resistance, as well as, Lucas Felt president and CEO of The Medical Memory and Steve Kraus of Bessemer Venture Partners.
